Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

AstraZeneca vaccine linked to rare blood clots, according to EMA official 

By Brian Buntz | April 6, 2021

AstraZeneca-OxfordEuropean Medicines Agency (EMA) official Marco Cavaleri said there was a link between AstraZeneca’s COVID-19 vaccine and rare reports of blood clots, including pulmonary embolism, deep vein thrombosis and thrombocytopenia, according to a Reuters report.

Two separate research groups in Europe had reached similar conclusions regarding the blood clots in March.

AstraZeneca had previously downplayed the possibility that its COVID-19 vaccine is linked to such events. The company did not immediately respond to a request for a comment.

The benefits of the vaccine, which was jointly developed by AstraZeneca and Oxford University, still outweigh the risks, said Marco Cavaleri, head of health threats and vaccine strategy, in an interview with Rome’s Il Messaggero paper.

EMA is poised to make a formal announcement regarding the subject, Cavaleri said.

The EMA press office itself notes that it “has not yet reached a conclusion, and the review is currently ongoing.”

Several countries have halted or constrained the use of the vaccine over the possibility that the vaccine could be linked to blood clot issues. Germany and the Netherlands have stopped using the vaccine in patients under the age of 60. The majority of patients with rare blood clot problems were between the ages of 25 and 65.

The AstraZeneca vaccine will likely be the fourth to win emergency use authorization in the U.S. The company is, however, searching for a contract manufacturer to produce the vaccine following allegations that its partner Emergent BioSolutions had quality control problems. The company refutes those claims.


Filed Under: Infectious Disease, Neurological Disease
Tagged With: AstraZeneca plc, blood clot, blood clots, coronavirus, covid-19, COVID-19 vaccine, COVID-19 vaccine trial, COVID-19 vaccines, deep vein thrombosis, pulmonary embolism, thrombocytopenia
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Bavarian Nordic
U.S. purchases more monkeypox vaccine doses from Bavarian Nordic
covid-19 vaccine
FDA backs COVID-19 boosters with BA.4/5 spike proteins for fall
Pfizer-BioNTech
Pfizer and BioNTech forge new COVID-19 vaccine deal with U.S. government
Icosavax
Icosavax shares positive early results for VLP vaccine candidate against RSV

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50